Please assess the completion status of the following clinical trial:

Trial Title: Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo total joint arthroplasty at area hospital~* Primary unilateral total hip or knee arthroplasty scheduled within approximately 6 months of the initial evaluation clinic visit~Exclusion Criteria:~* Patients scheduled to undergo a revision or bilateral procedure~* Receiving chronic opioid therapy, defined as the use of opioids on most days for \> 3 month~* Allergy to opioids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- CYP2D6-guided opioid therapy (Type: ACTIVE_COMPARATOR): Participants randomized to the CYP2D6-guided arm will have their CYP2D6 genotyping completed prior to surgery (in the absence of any genotyping error) with results reported in the electronic health record (EHR). Patients will be categorized as CYP2D6 PM, IM, NM, or UM based on CYP2D6 genotype/activity score and FDA guidance on drug interactions. Strong inhibitors (e.g. bupropion, fluoxetine, paroxetine) phenoconvert patients to PMs, with moderate inhibitors (e.g. duloxetine, fluvoxamine) reducing CYP2D6 activity scores by 50%.
- Usual Care (Type: NO_INTERVENTION): Participants randomized to the usual care arm will have their DNA collected at the start of the study and stored at the lab until after they have completed their surgery and the 2-week follow-up, at which time, their sample was genotyped with the results reported in the EHR.

Based on this trial design, predict the completion outcome and termination type (if applicable).